Teva Pharmaceutical Industries Limited
TEVA
$36.77
$0.250.69%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 546.84% | 221.62% | 185.97% | 174.24% | 65.12% |
| Total Depreciation and Amortization | -3.32% | -3.10% | -5.19% | -4.07% | -5.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.62% | -79.81% | -73.30% | -28.61% | 51.48% |
| Change in Net Operating Assets | -15.46% | -101.41% | -214.48% | -1,905.88% | -118.10% |
| Cash from Operations | 36.55% | 35.39% | 32.24% | -42.56% | 19.01% |
| Capital Expenditure | -10.00% | -8.18% | -0.60% | 0.00% | -2.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | 100.00% |
| Divestitures | -20.59% | -1.67% | -20.93% | -2.56% | 518.18% |
| Other Investing Activities | -8.14% | -3.26% | -4.60% | -9.67% | 3.00% |
| Cash from Investing | -95.81% | -9.89% | -6.94% | -13.13% | 12.39% |
| Total Debt Issued | -100.00% | -- | -- | -- | 229.29% |
| Total Debt Repaid | 89.11% | 7.81% | -151.01% | -229.95% | -63.89% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 120.05% | 120.00% | -124.67% | -54.43% | -16.29% |
| Cash from Financing | 83.37% | 88.36% | -20.10% | -69.23% | -6.30% |
| Foreign Exchange rate Adjustments | -315.79% | -64.00% | 112.07% | -700.00% | 116.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,656.25% | 258.08% | 245.95% | -204.30% | 76.70% |